pubmed-article:14676209 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:14676209 | lifeskim:mentions | umls-concept:C1140680 | lld:lifeskim |
pubmed-article:14676209 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
pubmed-article:14676209 | lifeskim:mentions | umls-concept:C0042071 | lld:lifeskim |
pubmed-article:14676209 | lifeskim:mentions | umls-concept:C1510411 | lld:lifeskim |
pubmed-article:14676209 | lifeskim:mentions | umls-concept:C0334227 | lld:lifeskim |
pubmed-article:14676209 | lifeskim:mentions | umls-concept:C0037083 | lld:lifeskim |
pubmed-article:14676209 | lifeskim:mentions | umls-concept:C0041904 | lld:lifeskim |
pubmed-article:14676209 | lifeskim:mentions | umls-concept:C0033414 | lld:lifeskim |
pubmed-article:14676209 | lifeskim:mentions | umls-concept:C2699153 | lld:lifeskim |
pubmed-article:14676209 | lifeskim:mentions | umls-concept:C0018270 | lld:lifeskim |
pubmed-article:14676209 | lifeskim:mentions | umls-concept:C1269955 | lld:lifeskim |
pubmed-article:14676209 | lifeskim:mentions | umls-concept:C0162493 | lld:lifeskim |
pubmed-article:14676209 | lifeskim:mentions | umls-concept:C1710082 | lld:lifeskim |
pubmed-article:14676209 | lifeskim:mentions | umls-concept:C1314939 | lld:lifeskim |
pubmed-article:14676209 | pubmed:issue | 10 | lld:pubmed |
pubmed-article:14676209 | pubmed:dateCreated | 2004-3-1 | lld:pubmed |
pubmed-article:14676209 | pubmed:abstractText | Urokinase-type plasminogen activator (uPA) has been implicated in tumor cell invasion and metastasis. We reported previously that transforming growth factor (TGF)-beta1 induces a dose- and time-dependent up-regulation of uPA mRNA and protein in highly invasive human ovarian cancer cell line HRA, leading to invasion. To further elucidate the mechanism of the invasive effect of TGF-beta1, we investigated which signaling pathway transduced by TGF-beta1 is responsible for this effect. Here, we show that 1) nontoxic concentrations of TGF-beta1 activated Src kinase; 2) TGF-beta1 rapidly phosphorylates ERK1/2 and Akt, but not p38; 3) pharmacological Src inhibitor PP2 or antisense (AS) c-Src oligodeoxynucleotide (ODN) treatment reduced TGF-beta1-induced phosphorylation of ERK1/2 and Akt by 85-90% compared with controls; 4) pharmacological inhibition of MAPK by PD98059 abrogated TGF-beta1-mediated Akt stimulation, whereas TGF-beta1-induced ERK1/2 stimulation was not inhibited by PI3K inhibitor LY294002 or AS-PI3K ODN transfection; 5) up-regulation of uPA mRNA in response to TGF-beta1 was almost totally blocked by PP2 and PD98059 and partially ( approximately 55%) by LY294002; 6) TGF-beta1-induced uPA mRNA up-regulation was inhibited by treatment with AS ODNs to c-Src or PI3K by 90 or 60%, respectively, compared with control ODN treatment; and 7) blockade of the release of the transcription factor NF-kappaB by pyrrolidinedithiocarbamate reduced the TGF-beta1-induced activation of the uPA gene by approximately 65%. In addition, curcumin, a blocker of the transcriptional factor AP-1, partially (35%) canceled this effect. Taken together, these data support a role for TGF-beta1 activation of two distinct pathways (Src-MAPK-PI3K-NF-kappaB-dependent and Src-MAPK-AP-1-dependent) for TGF-beta1-dependent uPA up-regulation and promotion of invasion. | lld:pubmed |
pubmed-article:14676209 | pubmed:language | eng | lld:pubmed |
pubmed-article:14676209 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14676209 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:14676209 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14676209 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14676209 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14676209 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14676209 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14676209 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:14676209 | pubmed:month | Mar | lld:pubmed |
pubmed-article:14676209 | pubmed:issn | 0021-9258 | lld:pubmed |
pubmed-article:14676209 | pubmed:author | pubmed-author:KobayashiHiro... | lld:pubmed |
pubmed-article:14676209 | pubmed:author | pubmed-author:SuzukiMikaM | lld:pubmed |
pubmed-article:14676209 | pubmed:author | pubmed-author:KanayamaNaohi... | lld:pubmed |
pubmed-article:14676209 | pubmed:author | pubmed-author:TeraoToshihik... | lld:pubmed |
pubmed-article:14676209 | pubmed:author | pubmed-author:TanakaYoshiko... | lld:pubmed |
pubmed-article:14676209 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:14676209 | pubmed:day | 5 | lld:pubmed |
pubmed-article:14676209 | pubmed:volume | 279 | lld:pubmed |
pubmed-article:14676209 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:14676209 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:14676209 | pubmed:pagination | 8567-76 | lld:pubmed |
pubmed-article:14676209 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
pubmed-article:14676209 | pubmed:meshHeading | pubmed-meshheading:14676209... | lld:pubmed |
pubmed-article:14676209 | pubmed:meshHeading | pubmed-meshheading:14676209... | lld:pubmed |
pubmed-article:14676209 | pubmed:meshHeading | pubmed-meshheading:14676209... | lld:pubmed |
pubmed-article:14676209 | pubmed:meshHeading | pubmed-meshheading:14676209... | lld:pubmed |
pubmed-article:14676209 | pubmed:meshHeading | pubmed-meshheading:14676209... | lld:pubmed |
pubmed-article:14676209 | pubmed:meshHeading | pubmed-meshheading:14676209... | lld:pubmed |
pubmed-article:14676209 | pubmed:meshHeading | pubmed-meshheading:14676209... | lld:pubmed |
pubmed-article:14676209 | pubmed:meshHeading | pubmed-meshheading:14676209... | lld:pubmed |
pubmed-article:14676209 | pubmed:meshHeading | pubmed-meshheading:14676209... | lld:pubmed |
pubmed-article:14676209 | pubmed:meshHeading | pubmed-meshheading:14676209... | lld:pubmed |
pubmed-article:14676209 | pubmed:meshHeading | pubmed-meshheading:14676209... | lld:pubmed |
pubmed-article:14676209 | pubmed:year | 2004 | lld:pubmed |
pubmed-article:14676209 | pubmed:articleTitle | Transforming growth factor-beta1-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells. | lld:pubmed |
pubmed-article:14676209 | pubmed:affiliation | Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, Handayama 1-20-1, Hamamatsu, Shizuoka, 431-3192, Japan. | lld:pubmed |
pubmed-article:14676209 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:14676209 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
entrez-gene:7040 | entrezgene:pubmed | pubmed-article:14676209 | lld:entrezgene |
http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:14676209 | lld:entrezgene |
lhgdn:association:55952 | lhgdn:found_in | pubmed-article:14676209 | lld:lhgdn |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14676209 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14676209 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14676209 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14676209 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14676209 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14676209 | lld:pubmed |